Physician profile
Luis Gonzalez
NPI 1649220138
$2,062.90
in general payments reported to CMS, 2019-2025
10 companies · $613 in 2025
The $613 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2021: $248 · 2022: $209 · 2023: $286 · 2024: $541 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $950.82 | 2022-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $335.16 | 2019-2025 | Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $226.08 | 2024-2025 | Libtayo |
| Blueprint Medicines Corporation | $125.88 | 2023 | Ayvakit |
| Genzyme Corporation | $123.95 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $112.34 | 2021 | |
| Novartis Pharmaceuticals Corporation | $92.48 | 2019 | |
| Inari Medical, INC. | $61.93 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $21.20 | 2023 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.